Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSF Swallowing Safety in ALS
NCT03679975Phase 2Terminated
- Sponsor
- Aquestive Therapeutics
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riluzole in amyotrophic lateral sclerosis (ALS), sponsored by Aquestive Therapeutics. Started Apr 2018; status: terminated.
02
Drugs
riluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03679975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679975.